Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2003 October;44(5) > The Journal of Cardiovascular Surgery 2003 October;44(5):597-603





Rivista di Chirurgia Cardiaca, Vascolare e Toracica

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632




The Journal of Cardiovascular Surgery 2003 October;44(5):597-603

lingua: Inglese

Midterm experience with the Sorin Bicarbon heart valve prosthesis for rheumatic disease

Erdil N. 1, Cetin L. 2, Ates S. 2, Demirkilic U. 3, Sener E. 2, Tatar H. 3, Cakir B. 4

1 Depart­ment of Car­di­o­vas­cular Sur­gery, Inonu Uni­ver­sity, ­Turgut ­Ozal Med­ical ­Center, Mal­atya, ­Turkey
2 Depart­ment of Car­di­o­vas­cular Sur­gery, Alkan Hos­pital, ­Ankara, ­Turkey
3 Depart­ment of Car­di­o­vas­cular Sur­gery, Gülhane Mil­i­tary Hos­pital, ­Ankara, ­Turkey
4 Depart­ment of ­Public ­Health, Faculty of Med­i­cine, Hacet­tepe Uni­ver­sity, ­Ankara, ­Turkey

Full text temporaneamente non disponibile on-line. Contattaci  

Back­ground. In ­this ­study, we ­present a ­single ­center expe­ri­ence ­with ­Bicarbon ­bileaflet ­valve in 307 ­patients ­with rheu­matic ­heart dis­ease.
­Methods. ­Between ­August 1998 and Sep­tember 2000, 307 ­patients under­went ­heart ­valve replace­ment ­using the ­Bicarbon ­bileaflet ­valve (­Sorin Bio­medica, ­Saluggia, ­Italy) ­with an ­average age of 47.19±13.21 ­years (­range 14 to 80 ­years), con­sisting of 147 ­males and 160 ­females at ­Alkan Hos­pital, Car­di­o­vas­cular Sur­gery Depart­ment. ­Aortic ­valve replace­ment (AVR) was per­formed in 77 ­patients, ­mitral ­valve replace­ment (MVR) in 156 ­patients and ­double ­valve replace­ment (DVR) in 74 ­patients.
­Results. The ­early mor­tality ­rate was 3.3% (10/307) and ­there was no ­late mor­tality. The actu­arial sur­vival ­rate, ­including hos­pital mor­tality, was 96.74±1.01% for the ­whole ­group, 96.5±1.5% for the MVR ­group, 97.4±1.8% for the AVR ­group and 97.3±1.9% for the DVR ­group at 35 ­months. One ­patient had obstruc­tive ­valve throm­bosis ­with MVR. The 35 ­months actu­arial ­freedom ­from ­valve throm­bosis was 99.58±0.4% for the ­whole ­group. ­Four ­patients ­were reop­er­ated and the ­35 ­months actu­arial ­freedom ­from reop­er­a­tion was 98.53±0.7% for the ­whole ­group, 98.65±0.9% for the MVR ­group, 96.73±02% for the DVR ­group and 100% for the AVR ­group. No ­instances of per­i­val­vular ­leak, hemol­ysis, endo­car­ditis or embo­lism ­were ­observed ­during the ­entire ­follow-up ­period. ­Mean ­follow-up dura­tion was 16.5±7.9 ­months (­ranged 4 to 35 ­months).
Con­clu­sions. We ­have pre­sented our mid-­term ­results ­with the ­Sorin ­Bicarbon ­bileaflet ­valve in ­patients ­with rheu­matic ­heart dis­ease, ­which pro­vided ­good clin­ical per­for­mance com­bined ­with metic­u­lous ­patient ­care and ­advanced sur­gical tech­niques.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail